Literature DB >> 15037714

Pilot trial of albuterol in Duchenne and Becker muscular dystrophy.

E G Fowler1, M C Graves, G T Wetzel, M J Spencer.   

Abstract

The authors conducted a randomized, crossover, double-blind, placebo-controlled pilot study of albuterol in nine boys with dystrophinopathies. Primary outcomes were 1) isometric knee extensor and flexor strength; and 2) manual muscle testing (MMT). Isometric knee extensor strength and MMT scores were significantly higher in patients taking albuterol vs placebo. Therefore, 12-week treatment with extended-release albuterol may increase strength in patients with dystrophinopathies. A larger, double-blind, randomized study is necessary to confirm these results.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15037714     DOI： 10.1212/01.wnl.0000118530.71646.0f

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  8 in total

1.  Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.

Authors:  James G Ryall; Martin N Sillence; Gordon S Lynch
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

2.  Interleukin-15 administration improves diaphragm muscle pathology and function in dystrophic mdx mice.

Authors:  Leah J Harcourt; Anna Greer Holmes; Paul Gregorevic; Jonathan D Schertzer; Nicole Stupka; David R Plant; Gordon S Lynch
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

3.  Therapeutic developments in spinal muscular atrophy.

Authors:  Douglas M Sproule; Petra Kaufmann
Journal:  Ther Adv Neurol Disord       Date:  2010-05       Impact factor: 6.570

4.  Adjunctive β2-agonists reverse neuromuscular involvement in murine Pompe disease.

Authors:  Songtao Li; Baodong Sun; Mats I Nilsson; Andrew Bird; Mark A Tarnopolsky; Beth L Thurberg; Deeksha Bali; Dwight D Koeberl
Journal:  FASEB J       Date:  2012-09-19       Impact factor: 5.191

5.  Aquatic photolysis of β2-agonist salbutamol: kinetics and mechanism studies.

Authors:  Lei Zhou; Qi Wang; Ya Zhang; Yuefei Ji; Xi Yang
Journal:  Environ Sci Pollut Res Int       Date:  2016-12-27       Impact factor: 4.223

Review 6.  cAMP signaling in skeletal muscle adaptation: hypertrophy, metabolism, and regeneration.

Authors:  Rebecca Berdeaux; Randi Stewart
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-02-21       Impact factor: 4.310

7.  Influence of β2 adrenergic receptor genotype on risk of nocturnal ventilation in patients with Duchenne muscular dystrophy.

Authors:  Eli F Kelley; Troy J Cross; Eric M Snyder; Craig M McDonald; Eric P Hoffman; Luca Bello
Journal:  Respir Res       Date:  2019-10-16

8.  Role of phosphodiesterase 4 expression in the Epac1 signaling-dependent skeletal muscle hypertrophic action of clenbuterol.

Authors:  Yoshiki Ohnuki; Daisuke Umeki; Yasumasa Mototani; Kouichi Shiozawa; Megumi Nariyama; Aiko Ito; Naoya Kawamura; Yuka Yagisawa; Huiling Jin; Wenqian Cai; Kenji Suita; Yasutake Saeki; Takayuki Fujita; Yoshihiro Ishikawa; Satoshi Okumura
Journal:  Physiol Rep       Date:  2016-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.